Human Immune System Mice
- Products
- Animal Models
- Human Immune System Mice
- huPBMC-NCG
huPBMC-NCG
Type : PBMC Humanized Mice
Strain Number: T057056
Background Strain: NCG [T001475]
The huPBMC-NCG mouse model is established by transplanting Peripheral Blood Mononuclear Cells (PBMCs) from healthy donors into highly immunodeficient NCG mice to create a human immune system-reconstituted model. This model supports rapid immune cell engraftment, primarily consisting of T cells, making it suitable for preclinical evaluation of anti-tumor therapies. However, due to the fast expansion of human T cells, these cells can recognize and attack murine tissues, leading to graft-versus-host disease (GvHD) within 5–7 weeks post-injection. This feature also makes the model ideal for studying anti-GvHD therapeutics. To minimize variability caused by different PBMC donors, we have established a screened huPBMC donor library to ensure consistent immune reconstitution across experiments.
Preclinical anti-tumor efficacy studies and safety evaluation
Short-term efficacy evaluation
Evaluation of anti-GvHD drugs
Human PBMCs were injected through the caudal vein (1×107cells) into NCG mice for huPBMC reconstitution. The proportion of human CD45+ leukocytes in the peripheral blood of huPBMC-NCG mice gradually increased over time, with the mean proportion of human leukocytes exceeding 50% by the third week, predominantly CD3+ T cells. Due for development of GvHD, huPBMC-NCG mice have a relatively short treatment period from Week-2 to week-5 post PBCM injection.
Features of HuHSC-NCG
1.Predominant with T-cells
2.Relatively short lifespan due to GvHD
- GvHD can be avoided using NCG-MHC-dKO
- Hu et al. (2022). Interferon-α potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discovery, doi:10.1158/2159-8290.CD-21-1022.
- Ma et al. (2021). Biomimetic Nanoerythrosome‐Coated Aptamer‐DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐positive Breast Cancer. Advanced Materials, 2109609.
- Song et al. (2022). Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma. Molecular Cancer, 21(1): 43.
- Zhang et al. (2021). Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metabolism, 33(6): 1111–1123.e4.
Axiocell Biotech Sdn Bhd.
Suite 2-5, Level 18, Plaza Azalea 10, Persiaran Bandaraya, Seksyen 14, 40000 Shah Alam, Selangor.
© 2025 AXIOCELL BIOTECH. All rights reserved.
Developed by Infinicore – Design by LeMoon